‘We’re Doing God’s Work’: What We Heard This Week

Derick Alison
Derick Alison
3 Min Read

“Treating patients and getting them well, it’s something — we’re doing God’s work.” — Steven Feldman, MD, PhD, of Wake Forest University School of Medicine in North Carolina, on treating patients with atopic dermatitis.

“It’s kind of overkill.” — Raman Madan, MD, a dermatologist with Northwell Health in New York, on people under 25 getting cosmetic treatment with Botox.

“It is not out of the realm of possibility that one or two out of 10,000 patients could develop T-cell lymphoma.” — Frederick Locke, MD, of the Moffitt Cancer Center in Tampa, Florida, discussing the FDA’s investigation of malignancy after autologous chimeric antigen receptor (CAR) T-cell therapies.

“There is this interconnection between the brain and the neck muscles.” — Nico Sollmann, MD, of University Hospital Ulm in Germany, discussing the link between inflammation and edema of the trapezius muscles with headaches.

“You’re there, you’re sick, you get your appendix out, then you never have to worry about your appendix ever again.” — David Flum, MD, MPH, of the University of Washington in Seattle, on appendectomy versus antibiotics in light of Stephen Colbert’s recent ruptured appendix.

“I control all the docs in the county — I give myself a good price and I charge all the other plans 30% more.” — Glenn Melnick, PhD, a healthcare economist at the University of Southern California, on potential pitfalls of health insurers financially investing in medical services.

“The study hugely adds to risk reduction ideas that were mostly theoretical up until this point.” — Kristine Yaffe, MD, of the University of California San Francisco, discussing a personal coaching intervention that modestly improved cognition in older adults at high risk for dementia.

“There’s definitely a race to the finish line to see which one gets approved first.” — Hirsh Trivedi, MD, of Cedars-Sinai Medical Center in Los Angeles, on the pipeline of metabolic dysfunction-associated steatohepatitis treatments (MASH).

“As voice cloning has improved, I’ve been seeing an increase in these types of fakes.” — Hany Farid, PhD, of the University of California Berkeley, on social media ads of AI-cloned clinicians.

Source link

Share this Article
Leave a comment
adbanner